Drugs / ET140202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03998033 | May 2019 → Dec 2020 | hepatocellular carcinoma | Eureka Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET140202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03998033 ↗ |
| Action | Deplete | “capable of mediating cell killing by targeting tumor specific intracellular antigens” NCT03998033 ↗ |
| Modality | Cell therapy | “genetically modified autologous T-cell therapy” NCT03998033 ↗ |